Neslihan Aksu1, Şükriye Damla Kara2, Taner Aksu3, Vefa Atansay1, Ayhan Nedim Kara1

1Department of Orthopedics and Traumatology, Demiroğlu Bilim University Faculty of Medicine, İstanbul, Turkey
2Department of Neurology, University of South Florida, Florida, USA
3Department of Orthopedics and Traumatology, Bahçeşehir University Faculty of Medicine, İstanbul, Turkey

Keywords: Alkylating agent, bone cancer, chemical agent, chemotherapy, etiologic factors, malign bone tumor, radiotherapy


Primary malignant bone tumors constitute a very small part of adult cancers. However, osteosarcomas constitute approximately half of all malignant bone tumors in ages between 15 to 29 years. This is followed by Ewing sarcoma primitive neuroectodermal tumors of bone and chondrosarcoma. Factors affecting malignant bone tumors include genetics, race, sex, growth and development age, radiotherapy treatment, radioactive substances, chemotherapy treatment, trauma, chemical substances, predisposing lesions, X-rays, and immune deficiency. Determining possible familial and genetic risk factors and predisposing agents and therefore informing families on avoiding physical and chemical exposure may be the most important factors in preventing malignancy. In this article, we aimed to discuss factors affecting the development of malignant bone tumors.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.